Skip to main content
Journal cover image

Uricase and other novel agents for the management of patients with treatment-failure gout.

Publication ,  Journal Article
Sundy, JS; Hershfield, MS
Published in: Curr Rheumatol Rep
June 2007

Successful management of chronic gout depends on reducing body pools of urate. The benchmark of success is to maintain serum urate levels at less than 6 mg/dL using therapies such as probenecid or allopurinol. In a subset of patients with gout, these medications fail to achieve this benchmark, resulting in ongoing signs and symptoms characteristic of treatment-failure gout. Potential therapies now in clinical development show promise for treating this refractory patient population. In this article, we review the clinical characteristics associated with treatment-failure gout and discuss recent data from clinical trials of febuxostat and uricase.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Curr Rheumatol Rep

DOI

ISSN

1523-3774

Publication Date

June 2007

Volume

9

Issue

3

Start / End Page

258 / 264

Location

United States

Related Subject Headings

  • Uric Acid
  • Urate Oxidase
  • Treatment Failure
  • Thiazoles
  • Recombinant Proteins
  • Randomized Controlled Trials as Topic
  • Humans
  • Gout Suppressants
  • Gout
  • Febuxostat
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Sundy, J. S., & Hershfield, M. S. (2007). Uricase and other novel agents for the management of patients with treatment-failure gout. Curr Rheumatol Rep, 9(3), 258–264. https://doi.org/10.1007/s11926-007-0041-y
Sundy, John S., and Michael S. Hershfield. “Uricase and other novel agents for the management of patients with treatment-failure gout.Curr Rheumatol Rep 9, no. 3 (June 2007): 258–64. https://doi.org/10.1007/s11926-007-0041-y.
Sundy JS, Hershfield MS. Uricase and other novel agents for the management of patients with treatment-failure gout. Curr Rheumatol Rep. 2007 Jun;9(3):258–64.
Sundy, John S., and Michael S. Hershfield. “Uricase and other novel agents for the management of patients with treatment-failure gout.Curr Rheumatol Rep, vol. 9, no. 3, June 2007, pp. 258–64. Pubmed, doi:10.1007/s11926-007-0041-y.
Sundy JS, Hershfield MS. Uricase and other novel agents for the management of patients with treatment-failure gout. Curr Rheumatol Rep. 2007 Jun;9(3):258–264.
Journal cover image

Published In

Curr Rheumatol Rep

DOI

ISSN

1523-3774

Publication Date

June 2007

Volume

9

Issue

3

Start / End Page

258 / 264

Location

United States

Related Subject Headings

  • Uric Acid
  • Urate Oxidase
  • Treatment Failure
  • Thiazoles
  • Recombinant Proteins
  • Randomized Controlled Trials as Topic
  • Humans
  • Gout Suppressants
  • Gout
  • Febuxostat